Brief: Gensight Biologics Says Study Data Shows Sustained Efficacy 3 Years After Injection Of Lumevoq

Gensight Biologics SA

31/08/2021 06:37

Aug 31 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS ANNOUNCES PUBLICATION OF RESTORE STUDY
DATA
DEMONSTRATING SUSTAINED EFFICACY 3 YEARS AFTER UNILATERAL
INJECTION OF LUMEVOQ®
    * TREATMENT EFFECT OF LUMEVOQ® WAS MAINTAINED AT YEAR 3
AFTER
TREATMENT ADMINISTRATION, WITH MEAN VISUAL ACUITY ACHIEVING AN
ON-CHART LEVEL OF 1.26 LOGMAR
    * QUALITY OF LIFE SCORES CONTINUED TO IMPROVE BETWEEN YEAR 2
AND
YEAR 3 AFTER TREATMENT ADMINISTRATION

Source text for Eikon:  ID:nBwbzXF58a 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))